Strategies to optimize CAD prevention in modern cardiology. The 'Marburg CAD Prevention Project'

Herz

Volumn 25, Issue 2, 2000, Pages 113-116

  Schaefer, Juergen R ^b   Simon, Bernd ^c   Soufi, Muhidien ^c   Sattler, Alexander ^c   Noll, Bernd ^c   Herzum, Matthias ^c   Maisch, Bernhard ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c NONE

Author keywords

CAD prevention; CARDDAS ; Deadly trias; Elevated homocystein; Elevated Lp(a); Low HDL; Marburg CAD Prevention Project

Indexed keywords

CARDIOLOGY; COMPUTER PROGRAM; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; PROPHYLAXIS; REVIEW; SECONDARY PREVENTION;

EID: 0034053167     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00001948     Document Type: Review

References (16)

1. Bucher HC, Griffith LE, Guyatt GH. Effect of HMG CoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998;128:89-95.
2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615.
3. Pyörälä K, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997;14:614.
4. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998;97:1446.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001.
6. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (45). Lancet 1994;344:1383.
7. Schaefer JR. Präventive Kardiologie. Prophylaxe der koronaren Herzkrankheit. Stuttgart-New York: Schattauer, 1998.
8. Schaefer JR, Herzum M. Arteriosklerose und koronare Herzerkrankung-Stärken und Lücken im klassischen Risikofaktorenkonzept. Herz 1998;23:153.
9. Schaefer JR, Herzum M, Maisch B. Prävention der koronaren Herzerkrankung - "evidence based medicine" in der Lipidsenkertherapie. Herz 1999;24:3.
10. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301.abstract.
11. Simon BC, Schaefer JR, Gruenfeld M, et al. On-line documentation of diagnostic and interventional procedures and automated assessment of CAD prevention recommendations. Comput Cardiol 1999;26:383.
12. Soufi M, Noll B, Herzum M, et al. Labordiagnostik in der präventiven Kardiologie. Herz 1999;13.
13. Steinmetz A, Noll B, Maisch B, et al. Lipidsenkende Therapie zur Primärprävention der koronaren Herzkrankheit - pro lipidsenkende Therapie. Z Kardiol 1998;87:205.
14. Szucs TD, Guggenberger G, Berger K, et al. Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten. Eine Analyse für Deutschland auf der Grundlage der CARE-Studie. Herz 1998;23:319.
15. The Long-Term Intervention With Pravastatin In Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349.
16. West of Scotland Coronary Prevention Study Group: Influence of Pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation 1998;97:1440.